Innate Pharma Stock Technical Analysis
| IPHA Stock | USD 1.76 0.03 1.68% |
As of the 27th of January, Innate Pharma retains the Risk Adjusted Performance of (0.02), market risk adjusted performance of (0.33), and Standard Deviation of 4.84. Innate Pharma technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.
Innate Pharma Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Innate, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to InnateInnate Pharma's Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Innate Pharma Analyst Consensus
| Target Price | Advice | # of Analysts | |
| 5.75 | Buy | 3 | Odds |
Most Innate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Innate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Innate Pharma, talking to its executives and customers, or listening to Innate conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. If investors know Innate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innate Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innate Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Innate Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Innate Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Innate Pharma.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Innate Pharma on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Innate Pharma or generate 0.0% return on investment in Innate Pharma over 90 days. Innate Pharma is related to or competes with Cardiff Oncology, Rani Therapeutics, Milestone Pharmaceuticals, Compugen, Corbus Pharmaceuticals, Molecular Partners, and Nuvectis Pharma. Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the trea... More
Innate Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Innate Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Innate Pharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 39.49 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.02 |
Innate Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Innate Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Innate Pharma's standard deviation. In reality, there are many statistical measures that can use Innate Pharma historical prices to predict the future Innate Pharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.34) |
Innate Pharma January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.33) | |||
| Mean Deviation | 2.66 | |||
| Coefficient Of Variation | (3,012) | |||
| Standard Deviation | 4.84 | |||
| Variance | 23.45 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.34) | |||
| Maximum Drawdown | 39.49 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.02 | |||
| Skewness | 3.19 | |||
| Kurtosis | 21.0 |
Innate Pharma Backtested Returns
Innate Pharma holds Efficiency (Sharpe) Ratio of -0.0372, which attests that the entity had a -0.0372 % return per unit of risk over the last 3 months. Innate Pharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Innate Pharma's Standard Deviation of 4.84, market risk adjusted performance of (0.33), and Risk Adjusted Performance of (0.02) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 0.5, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Innate Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Innate Pharma is expected to be smaller as well. At this point, Innate Pharma has a negative expected return of -0.17%. Please make sure to check out Innate Pharma's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if Innate Pharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.10 |
Insignificant predictability
Innate Pharma has insignificant predictability. Overlapping area represents the amount of predictability between Innate Pharma time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Innate Pharma price movement. The serial correlation of 0.1 indicates that less than 10.0% of current Innate Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.1 | |
| Spearman Rank Test | 0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Innate Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Innate Pharma Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Innate Pharma volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Innate Pharma Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Innate Pharma on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Innate Pharma based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Innate Pharma price pattern first instead of the macroeconomic environment surrounding Innate Pharma. By analyzing Innate Pharma's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Innate Pharma's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Innate Pharma specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2025 | 2026 (projected) | Dividend Yield | 0.002467 | 0.002344 | Price To Sales Ratio | 10.71 | 10.18 |
Innate Pharma January 27, 2026 Technical Indicators
Most technical analysis of Innate help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Innate from various momentum indicators to cycle indicators. When you analyze Innate charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.33) | |||
| Mean Deviation | 2.66 | |||
| Coefficient Of Variation | (3,012) | |||
| Standard Deviation | 4.84 | |||
| Variance | 23.45 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | (0.64) | |||
| Treynor Ratio | (0.34) | |||
| Maximum Drawdown | 39.49 | |||
| Value At Risk | (5.21) | |||
| Potential Upside | 4.02 | |||
| Skewness | 3.19 | |||
| Kurtosis | 21.0 |
Innate Pharma January 27, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Innate stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 16.81 | ||
| Daily Balance Of Power | (3.00) | ||
| Rate Of Daily Change | 0.98 | ||
| Day Median Price | 1.77 | ||
| Day Typical Price | 1.76 | ||
| Price Action Indicator | (0.02) |
Complementary Tools for Innate Stock analysis
When running Innate Pharma's price analysis, check to measure Innate Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innate Pharma is operating at the current time. Most of Innate Pharma's value examination focuses on studying past and present price action to predict the probability of Innate Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innate Pharma's price. Additionally, you may evaluate how the addition of Innate Pharma to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |